Highlight 2 in breast cancer
Dr. Laure-Anne Teuwen, medical oncologist at the university hospital of Antwerp highlighted a population-based study evaluating the prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer. Additionally, the 10-year update of the Short-HER trial, a phase 3 non-inferiority trial comparing 9 weeks versus 1 year of adjuvant trastuzumab in combination with chemotherapy in HER2-positive early breast cancer patients, was discussed.
With the educational support of:
